^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRCA mutation

    i
    Other names: BRCA, Breast cancer, early onset
    Related biomarkers:
    Expression
    CNA
    Others
    2d
    Management of incidental STIC lesions with and without BRCA mutations: a survey of current clinical practice in Austria, Germany, and Switzerland. (PubMed, Arch Gynecol Obstet)
    This survey demonstrates differences in the clinical management of isolated STIC across German-speaking countries, highlighting discrepancies between guideline recommendations and real-world practices. THIS STUDY IS REGISTERED IN THE GERMAN CLINICAL TRIALS REGISTER UNDER : DRKS00033112.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA1 mutation • BRCA mutation
    2d
    Interplay between ADP-Ribosylation and Androgen Receptor Function in Prostate Cancer. (PubMed, Curr Pharm Des)
    PARP enzymes regulate AR via MARylation and PARylation, with inhibitors such as Olaparib, which disrupts AR-PARP crosstalk...We also discuss how this complex regulatory network may contribute to the development of advanced prostate cancer therapies in the future. This could improve PARP inhibitor and AR signalling inhibitor combinations and allow more patients to benefit from them.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • TIPARP (TCDD Inducible Poly(ADP-Ribose) Polymerase)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    4d
    Do all multi-peak LED light-curing units emit similar light outputs? (PubMed, J Dent)
    HER2-low and HER2-zero TNBC represent biologically distinct subgroups. HER2-low tumors are enriched for luminal AR-like characteristics, while HER2-zero tumors exhibit basal-like, highly proliferative, and immunogenic features. Although treatment outcomes did not differ significantly, these findings suggest that HER2-low and HER2- zero TNBC may require different therapeutic approaches. Prospective studies are warranted to validate these findings and further explore tailored treatment strategies.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • AR (Androgen receptor) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • EGFR mutation • HER-2 negative • AR positive • BRCA mutation
    5d
    Matching-Adjusted Indirect Comparisons of PARP Inhibitor Combinations in Metastatic Castration-Resistant Prostate Cancer Across Key Populations. (PubMed, Oncologist)
    MAICs showed improved clinical benefit with TALA+ENZA versus OLAP+AAP and NIRA+AAP across multiple mCRPC populations and endpoints. Despite limitations of indirect comparisons, findings support TALA+ENZA as a first-line treatment option for mCRPC.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Xtandi (enzalutamide) • abiraterone acetate • prednisone
    5d
    Comprehensive review of current management and precision medicine in pancreatic cancer. (PubMed, J Chin Med Assoc)
    Systemic therapies, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, and NALIRIFOX, remain the cornerstone of therapies for metastatic disease, with precision medicine offering targeted options such as PARP inhibitors for BRCA-mutated tumors. Modern radiotherapy techniques including stereotactic body radiation therapy and particle therapy enhance local control and reduce toxicity. The integration of next-generation sequencing and multidisciplinary management is essential for improving pancreatic cancer outcomes.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • irinotecan • leucovorin calcium
    5d
    TEJAS-2: A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers (clinicaltrials.gov)
    P2, N=29, Terminated, Aurigene Discovery Technologies Limited | N=90 --> 29 | Trial completion date: May 2027 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Feb 2026; Patient recruitment problems.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability) • FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset)
    |
    MSI-H/dMMR • HER-2 amplification • KRAS wild-type • RAS wild-type • BRCA mutation
    |
    AUR-109
    5d
    LORIKEET: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=154, Completed, MacroGenics | Active, not recruiting --> Completed
    Trial completion
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    docetaxel • prednisone • lorigerlimab (MGD019)
    6d
    Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study) (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, M.D. Anderson Cancer Center | N=300 --> 0 | Trial completion date: Dec 2033 --> Apr 2026 | Initiation date: Aug 2026 --> Apr 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2031 --> Apr 2026
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation
    7d
    Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Chong Kun Dang Pharmaceutical
    New P1 trial
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    7d
    ITIL-306 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1, Terminated, Instil Bio | N=51 --> 1 | Trial completion date: Nov 2039 --> Mar 2026 | Active, not recruiting --> Terminated; The study was terminated early due to discontinuation of development of the investigational program
    Enrollment change • Trial completion date • Trial termination
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    cyclophosphamide • fludarabine IV • ITIL-306
    7d
    DENALI: A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=310, Recruiting, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | N=170 --> 310
    Enrollment change • Platinum resistant
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CCNE1 (Cyclin E1) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    azenosertib (ZN-c3)